A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs VCL HB01 (Primary) ; VCL HM01 (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vical
  • Most Recent Events

    • 20 Jun 2016 Results from this trial were presented at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference, according to a Vical media release.
    • 20 Jun 2016 Results published in a Vical media release.
    • 09 May 2016 Results will be presented at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference, according to a Vical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top